RT Journal Article
T1 Enhanced neuronal survival and BDNF elevation via long-term co-activation of galanin 2 (GALR2) and neuropeptide Y1 receptors (NPY1R): potential therapeutic targets for major depressive disorder
A1 Borroto Escuela, Dasiel Óscar
A1 Serrano-Castro, Pedro Jesús
A1 Sánchez-Pérez, José Andrés
A1 Barbancho-Fernández, Miguel Ángel
A1 Fuxe, Kjell
A1 Narváez-Peláez, Manuel
K1 Neuropéptidos
K1 Antidepresivos
K1 Neurobiología del desarrollo
AB Background: Major Depressive Disorder (MDD) is a prevalent and debilitating condition, necessitating novel therapeutic strategies due to the limited efficacy and adverse effects of current treatments. We explored how galanin receptor 2 (GALR2) and Neuropeptide Y1 Receptor (NPYY1R) agonists, working together, can boost brain cell growth and increase antidepressant-like effects in rats. This suggests new ways to treat Major Depressive Disorder (MDD).Research Design and Methods: In a controlled laboratory setting, adult naive Sprague-Dawley rats were administered directly into the brain’s ventricles, a method known as intracerebroventricular (ICV) administration, with GALR2 agonist (M1145), NPYY1R agonist, both, or in combination with a GALR2 antagonist (M871). Main outcome measures included long-term neuronal survival, differentiation, andbehavioral.Results: Co-administration of M1145 and NPYY1R agonist significantly enhanced neuronal survival and maturation in the ventral dentate gyrus, with a notable increase in Brain-Derived Neurotrophic Factor (BDNF) expression. This neurogenic effect was associated with an antidepressant-like effect, an outcome partially reversed by M871.Conclusions: GALR2 and NPYY1R agonists jointly promote hippocampal neurogenesis and exert antidepressant-like effects in rats without adverse outcomes, highlighting their therapeutic potential for MDD. The study’s reliance on an animal model and intracerebroventricular delivery warrants further clinical exploration to confirm these promising results.
PB Taylor & Francis
YR 2024
FD 2024-04-21
LK https://hdl.handle.net/10630/33423
UL https://hdl.handle.net/10630/33423
LA eng
NO Dasiel Borroto-Escuela, Pedro Serrano-Castro, Jose Andrés Sánchez-Pérez, Miguel Angel Barbancho-Fernández, Kjell Fuxe & Manuel Narváez (2024) Enhanced neuronal survival and BDNF elevation via long-term co-activation of galanin 2 (GALR2) and neuropeptide Y1 receptors (NPY1R): potential therapeutic targets for major depressive disorder, Expert Opinion on Therapeutic Targets, 28:4, 295-308, DOI: 10.1080/14728222.2024.2342517
NO This manuscript was funded by the UMA18-FEDERJA-100 and ProyExcel_00613, Junta de Andalucía, pain, to MN. Additional funding support came from Cátedra Imbrain: Neurociencia Integrada y Bionestar to MN. This work also received support from Stiftelsen Olle Engkvist Byggmästare in 2018 and 2021, as well as from the Swedish Medical Research Council [Grant No. 62X-00715-50-3] awarded to KF and DB-E. Additionally, funding was provided by Hjärnfonden [Grants F02018-0286 and F02019-0296], Karolinska Institutet Forskningsstiftelser 2022, EMERGIA 2020-39318 [Plan Andaluz de Investigación, Desarrollo e Innovación 2020], and CONSOLIDACION INVESTIGADORA [CNS2022-136008, Programa Estatal para Desarrollar, Atraer y Retener Talento, del Plan Estatal de Investigación Científica, Técnica y de Innovación 2021-2023] awarded to DB-E. DB-E is affiliated with the Academia de Biólogos Cubanos and the Observatorio Cubano de Neurociencias (Yaguajay, Cuba).
DS RIUMA. Repositorio Institucional de la Universidad de Málaga
RD 20 ene 2026